Zhejiang Jolly PharmaceuticalLTD Valuation

Is 300181 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300181 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300181 (CN¥16.59) is trading below our estimate of fair value (CN¥41.56)

Significantly Below Fair Value: 300181 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300181?

Key metric: As 300181 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300181. This is calculated by dividing 300181's market cap by their current earnings.
What is 300181's PE Ratio?
PE Ratio	22x
Earnings	CN¥517.55m
Market Cap	CN¥11.39b

300181 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	4.4x
Enterprise Value/EBITDA	16.8x
PEG Ratio	0.9x

Price to Earnings Ratio vs Peers

How does 300181's PE Ratio compare to its peers?

The above table shows the PE ratio for 300181 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.3x
300705 Hunan Jiudian Pharmaceutical	22.6x	25.5%	CN¥11.5b
600750 Jiang Zhong PharmaceuticalLtd	16.9x	13.1%	CN¥12.6b
600285 Henan Lingrui Pharmaceutical	17.3x	16.1%	CN¥11.7b
300573 Shenyang Xingqi PharmaceuticalLtd	40.4x	32.8%	CN¥14.1b
300181 Zhejiang Jolly PharmaceuticalLTD	22x	23.3%	CN¥11.4b

Price-To-Earnings vs Peers: 300181 is good value based on its Price-To-Earnings Ratio (22x) compared to the peer average (24.3x).

Price to Earnings Ratio vs Industry

How does 300181's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 300181 is good value based on its Price-To-Earnings Ratio (22x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 300181's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300181 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	22x
Fair PE Ratio	28.2x

Price-To-Earnings vs Fair Ratio: 300181 is good value based on its Price-To-Earnings Ratio (22x) compared to the estimated Fair Price-To-Earnings Ratio (28.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

-3.9%

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

-3.0%

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

-4.2%

-23.6%